Clinical trial of voriconazole in Europe and the United States

Research output: Contribution to journalArticle

Abstract

Aspergillus has recently replaced Candida as the primary cause of death due to fungal infection, making it urgent to find drugs with good activity against Aspergillus. The new azole antifungal voriconazole (VRCZ) showed greater effectiveness and tolerability against aspergillosis than the conventional gold standard, Amphotericin B (AMPH). It also improved the survival of invasive aspergillosis patients with unfavorable prognosis. Earlier treatment with VRCZ would be expected to result in even better effectiveness and survival. Empiric treatment with VRCZ is expected to effectively prevent the onset of aspergillosis in high-risk patients.

Original languageEnglish (US)
Pages (from-to)24-31
Number of pages8
JournalJapanese Journal of Chemotherapy
Volume53
Issue numberSUPPL. 2
StatePublished - Nov 2005

Fingerprint

Aspergillosis
Clinical Trials
Aspergillus
Azoles
Survival
Mycoses
Amphotericin B
Candida
Cause of Death
Therapeutics
Pharmaceutical Preparations
Voriconazole

Keywords

  • Aspergillosis
  • Combination therapy
  • Early treatment
  • Invasive pulmonary aspergillosis
  • Voriconazole

ASJC Scopus subject areas

  • Pharmacology

Cite this

Clinical trial of voriconazole in Europe and the United States. / Patterson, Thomas F.

In: Japanese Journal of Chemotherapy, Vol. 53, No. SUPPL. 2, 11.2005, p. 24-31.

Research output: Contribution to journalArticle

@article{41e95511bfa24f97b99341423c39d7cc,
title = "Clinical trial of voriconazole in Europe and the United States",
abstract = "Aspergillus has recently replaced Candida as the primary cause of death due to fungal infection, making it urgent to find drugs with good activity against Aspergillus. The new azole antifungal voriconazole (VRCZ) showed greater effectiveness and tolerability against aspergillosis than the conventional gold standard, Amphotericin B (AMPH). It also improved the survival of invasive aspergillosis patients with unfavorable prognosis. Earlier treatment with VRCZ would be expected to result in even better effectiveness and survival. Empiric treatment with VRCZ is expected to effectively prevent the onset of aspergillosis in high-risk patients.",
keywords = "Aspergillosis, Combination therapy, Early treatment, Invasive pulmonary aspergillosis, Voriconazole",
author = "Patterson, {Thomas F}",
year = "2005",
month = "11",
language = "English (US)",
volume = "53",
pages = "24--31",
journal = "Japanese Journal of Chemotherapy",
issn = "1340-7007",
publisher = "Japan Society of Chemotherapy",
number = "SUPPL. 2",

}

TY - JOUR

T1 - Clinical trial of voriconazole in Europe and the United States

AU - Patterson, Thomas F

PY - 2005/11

Y1 - 2005/11

N2 - Aspergillus has recently replaced Candida as the primary cause of death due to fungal infection, making it urgent to find drugs with good activity against Aspergillus. The new azole antifungal voriconazole (VRCZ) showed greater effectiveness and tolerability against aspergillosis than the conventional gold standard, Amphotericin B (AMPH). It also improved the survival of invasive aspergillosis patients with unfavorable prognosis. Earlier treatment with VRCZ would be expected to result in even better effectiveness and survival. Empiric treatment with VRCZ is expected to effectively prevent the onset of aspergillosis in high-risk patients.

AB - Aspergillus has recently replaced Candida as the primary cause of death due to fungal infection, making it urgent to find drugs with good activity against Aspergillus. The new azole antifungal voriconazole (VRCZ) showed greater effectiveness and tolerability against aspergillosis than the conventional gold standard, Amphotericin B (AMPH). It also improved the survival of invasive aspergillosis patients with unfavorable prognosis. Earlier treatment with VRCZ would be expected to result in even better effectiveness and survival. Empiric treatment with VRCZ is expected to effectively prevent the onset of aspergillosis in high-risk patients.

KW - Aspergillosis

KW - Combination therapy

KW - Early treatment

KW - Invasive pulmonary aspergillosis

KW - Voriconazole

UR - http://www.scopus.com/inward/record.url?scp=29644444213&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=29644444213&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:29644444213

VL - 53

SP - 24

EP - 31

JO - Japanese Journal of Chemotherapy

JF - Japanese Journal of Chemotherapy

SN - 1340-7007

IS - SUPPL. 2

ER -